Compare Natera Inc. Common Stock (NTRA) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Transocean Ltd — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while Transocean Ltd trades at $5.58 (market cap $6.31B). The key difference: Natera Inc. Common Stock is far larger — about 9× Transocean Ltd's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Transocean Ltd for 18 Days on average.
| NTRA | RIG | |
|---|---|---|
Market Cap | $57.03B | $6.31B |
Volume | 1,131,157 | 37,551,905 |
Sector | Health | Energy |
52-Week High | $425.64 | $7.58 |
52-Week Low | $179.42 | $3.23 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $56.18B | $10.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Transocean (RIG) trades at $5.65, up 0.89% today, with a bullish technical signal from moving averages. The company shows mixed fundamentals with strong revenue growth to $4.1B in 2026 but persistent net losses. Recent contract wins including an $80M Equatorial Guinea deal and DOJ approval for the $5.8B Valaris acquisition provide positive catalysts. Cash flow improvement is notable with operating cash flow reaching $995M in 2026.
RIG presents a speculative opportunity driven by offshore cycle strength and deleveraging potential, but high debt levels and negative profitability pose significant risks. Analyst consensus is divided with 39% buy ratings, reflecting optimism about contract backlog versus concerns about execution and financial leverage. The stock's upside depends on successful debt reduction and sustained offshore drilling demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
